Is the incidence and prevalence of inhibitors greater with recombinant products? Yes.
Aledort
L M
LM
Mount Sinai School of Medicine, New York, NY 10029-6574, USA. louis.aledort@mssm.edu
D000818:Animals; D001779:Blood Coagulation Factors / Q000276:immunology*; D006801:Humans; D015994:Incidence; D007518:Isoantibodies / Q000097:blood*; D015995:Prevalence; D011994:Recombinant Proteins / Q000276:immunology*; D012307:Risk Factors
D001779:Blood Coagulation Factors; D007518:Isoantibodies; D011994:Recombinant Proteins